- Home
- Automated
- List of product information
- DERMOVATE SCALP APPLICATION 0.05% W/W [SIN04499P]
DERMOVATE SCALP APPLICATION 0.05% W/W [SIN04499P]
Active ingredients: DERMOVATE SCALP APPLICATION 0.05% W/W
On this page
Product Info
DERMOVATE SCALP APPLICATION 0.05% W/W
[SIN04499P]
Product information
Active Ingredient and Strength | CLOBETASOL PROPIONATE - 0.05% W/W |
Dosage Form | LOTION |
Manufacturer and Country | ASPEN BAD OLDESLOE GMBH - GERMANY |
Registration Number | SIN04499P |
Licence Holder | GLAXOSMITHKLINE PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | D07AD01 |
Indications
Steroid responsive dermatoses of the scalp such as:
Psoriasis
Recalcitrant eczemas
Dosage and Administration
Pharmaceutical form: Scalp Application
Apply sparingly to the scalp night and morning until improvement occurs. As with other highly-active topical steroid preparations, therapy should be discontinued when control is achieved. Repeated short courses of DERMOVATE Scalp Application may be used to control exacerbations. If continuous steroid treatment is necessary, a less potent preparation should be used.
Avoid contact with the eyes. Hands should be washed after application.
Due to the flammable nature of DERMOVATE Scalp Application, patients should avoid smoking or being near an open flame during application and immediately after use.
Children
Children are more likely to develop local and systemic side effects of topical corticosteroids and, in general, require shorter courses and less potent agents than adults.
Care should be taken when using clobetasol propionate to ensure the amount applied is the minimum that provides therapeutic benefit.
Clobetasol propionate is contraindicated in children under 1 year of age.
Elderly
The greater frequency of decreased hepatic or renal function in the elderly may delay elimination if systemic absorption occurs. Therefore, the minimum quantity should be used for the shortest duration to achieve the desired clinical benefit.
Renal / Hepatic Impairment
In case of systemic absorption (when application is over a large surface area for a prolonged period) metabolism and elimination may be delayed therefore increasing the risk of systemic toxicity. Therefore, the minimum quantity should be used for the shortest duration to achieve the desired clinical benefit.
Contraindications
The following conditions should not be treated with DERMOVATE
Hypersensitivity to clobetasol, or to any of the excipients in the preparation
Infections of the scalp
DERMOVATE is contraindicated in dermatoses in children under one year of age, including dermatitis.
